Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Executive Summary
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance